Related Experiment Videos
The management of heart failure: a matter of definition?
1Cardiothoracic Centre-Liverpool NHS Trust, UK.
Insights
Heart failure is a complex condition with varied definitions and patient populations, complicating research. Current drug treatments for heart failure are empirical, with unpredictable patient responses necessitating individual therapy trials.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Heart failure encompasses diverse clinical entities, often characterized by fluid retention or reduced left ventricular contractility.
- Previous definitions varied, impacting the comparability of epidemiological studies and therapeutic trials.
- The heterogeneity of heart failure patient populations complicates research and treatment standardization.
Purpose of the Study:
- To highlight the ambiguity in defining heart failure and its implications for clinical research.
- To discuss the empirical nature of current drug treatments for heart failure.
- To emphasize the need for personalized treatment strategies and predictive markers for patient response.
Main Methods:
- Review of existing literature on heart failure definitions and treatment.
- Analysis of the challenges in comparing results from epidemiological studies and therapeutic trials.
- Examination of the unpredictable responses to common heart failure medications.
Main Results:
- Heart failure is not a single clinical entity, leading to varied patient cohort compositions in studies.
- Current drug therapies, including digoxin, ACE inhibitors, and beta-blockers, show unpredictable efficacy in individual patients.
- Distinguishing between etiological benefits and symptomatic relief in treatment outcomes is crucial.
Conclusions:
- The multifaceted nature of heart failure necessitates clearer diagnostic criteria for research and clinical practice.
- Personalized medicine approaches are essential due to unpredictable drug responses in heart failure management.
- Future research should focus on identifying biomarkers to predict patient response to heart failure therapies.
Abstract:
The term heart failure has become a label for more than one clinical entity. For many years heart failure has been used to denote patients with various heart diseases who have begun to suffer from fluid retention, pulmonary venous hypertension, or systemic venous hypertension, either alone or in combination. More recently, the term heart failure has been applied to the combination of effort intolerance and reduced left ventricular contractility due to ischemic heart disease or other myocardial disease. Comparison of the results of epidemiological studies and therapeutic trials is complicated by variation in the composition of the patient populations selected for study. Drug treatment of heart failure remains fairly empirical. Distinction should be made between immediate or prognostic benefits related to the etiological diagnosis, and benefits related specifically to prevention and relief of, for example, fluid retention, rhythm disturbances, or ventricular hypertrophy. The response of individual patients to several forms of drug treatment, including digoxin, ACE inhibitors, and beta-blockade, is unpredictable. Prospective identification of patients liable to respond well to these drugs is not yet possible, but would greatly assist the choice of treatment. At present, trial of therapy is required in each patient to establish benefit and to avoid long-term treatment of nonresponders.